- Trial phase
- Approved
- Time to market
- Already approved and commercially available in the US (FDA approved December 2024, label expanded July 2025) and EU (EMA approved December 2024, expanded July 2025).
- Why 3/10
- Alhemo is already approved and commercially launched in both the US (FDA approved December 2024 for inhibitor patients, expanded July 2025 for non-inhibitor patients) and EU (EMA approved December 2024, expanded July 2025). The pediatric extension application was withdrawn in September 2026. No hard binary catalyst (PDUFA, pivotal readout) is scheduled in the next 12 months. As an approved, marketed drug at a company dominated by GLP-1 therapies, Alhemo is a small part of Novo Nordisk's value.
Alhemo is already approved and launching commercially in both the US and EU. The next meaningful event would be quarterly sales disclosures from Novo Nordisk, but as a small part of a GLP-1-dominated portfolio, Alhemo-specific revenue is unlikely to move NVO shares. Watch for any future pediatric label expansion efforts or new clinical data at hematology congresses.
Price Chart
Executive Summary
Alhemo (concizumab) is a once-daily subcutaneous monoclonal antibody from Novo Nordisk approved for routine prophylaxis to prevent bleeding episodes in adults and children 12+ with hemophilia A or B, with or without inhibitors. The FDA initially approved it in December 2024 for inhibitor patients and expanded the label in July 2025 to include patients without inhibitors; EMA approvals followed a similar timeline. A pediatric extension to children under 12 was withdrawn in Europe in September 2026. Alhemo competes in a crowded hemophilia market against Roche's Hemlibra, Sanofi's Qfitlia, and Pfizer's Hympavzi. For Novo Nordisk (NVO), a $300B+ market cap company driven primarily by GLP-1 drugs, Alhemo is a small rare-disease asset with projected peak sales of $1-2B by 2030, making it a minor contributor to the overall investment thesis.
How It Works
Alhemo is a monoclonal antibody that blocks tissue factor pathway inhibitor (TFPI), a natural protein that slows down blood clotting. By blocking TFPI, Alhemo helps restore the blood's ability to clot, reducing the frequency of bleeding episodes in people with hemophilia A or B. It is given as a once-daily injection under the skin using a prefilled pen.
Trial Status
Alhemo's approval was supported by the Phase 3 explorer7 trial (hemophilia with inhibitors) and explorer8 trial (hemophilia without inhibitors). Longer-term follow-up data from explorer7 showed sustained efficacy and consistent safety. First-time results from the Phase 3 explorer10 trial in children under 12 with inhibitors were presented at ISTH 2026 (July 2026), showing an 82% reduction in annualized bleeding rate, though the EMA pediatric extension application was withdrawn in September 2026.
The Two-Sided Case
Upcoming Catalysts
- Quarterly sales disclosures from Novo Nordisk (next: Q4 2026 earnings, expected late January/early February 2027)
- Potential future resubmission of pediatric label extension if additional clinical data is generated
- Real-world evidence and long-term follow-up data from ongoing extension studies
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S 6-K NVO ·Originating report